Immunoreactivity to XXXX and @entity20442 antigens and correlation to survival in @entity151 ( @entity151 ).

@entity1 @entity15468 @entity242 @entity5 @entity41011 @entity20442 @entity16 @entity4731 @entity151 @entity320 @entity72208
UNASSIGNED: 7159 Background: Previous serological analysis of @entity151 cell lines identified members of the SOX Group B ( @entity15468 ) and @entity20442 proteins as highly immunogenic @entity5 antigens. @entity72208 are expressed in normal adult brain, testis and prostate as well as in many @entity151 cell lines. @entity20442 is expressed in normal brain and testis and is detected in @entity5 cell lines (9/11 @entity151 , 10/12 @entity320 , 7/7 NSCLC) as well as in colon, breast, head and neck, lung, bladder, @entity242 and @entity320 tissues. We assessed the prevalence and titers of the antibody response to these proteins and their correlation with survival in a group of @entity151 patients. METHODS: Serum samples from 70 @entity151 @entity1 were tested for SOX and @entity20442 immunoreactivity using a plaque assay. Titers of immunoreactive samples were determined by 10-fold serial dilutions. Clinical characteristics and survival were analyzed with respect to immunoreactivity and statistical analysis performed. RESULTS: Of 70 @entity151 @entity1 sera tested, 25.7% were seropositive for @entity15468 , 21.4% for @entity4731 , 10.0% for @entity41011 , and 15.7% for @entity20442 with titers as high as10(6). Antibody response was seen in 14/30 limited stage @entity1 and 10/25 extensive stage @entity1 . Analysis of 40 @entity1 with complete clinical data showed a statistically significant survival advantage in @entity1 with immunoreactivity to @entity41011 and/or @entity20442 (p=0.0175). A trend towards longer survival in @entity1 seropositive for any of the four proteins was also observed although it did not reach statistical significance. CONCLUSIONS: In this group of @entity151 @entity1 , there is a high incidence of immunoreactivity to @entity15468 and @entity20442 . @entity41011 immunoreactivity was associated with high titer @entity15468 and @entity4731 immunoreactivity. Seroreactivity to SOX Group B and @entity20442 is associated with prolonged survival in these @entity1 without clinically evident @entity16 . The presence of these antibodies may be a marker of a more indolent course of this disease and may be of interest as a vaccine target. No significant financial relationships to disclose.
